142 related articles for article (PubMed ID: 31945121)
1. Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A.
Castro JT; Oliveira GS; Nishigasako MA; Debrie AS; Miyaji EN; Soares-Schanoski A; Akamatsu MA; Locht C; Ho PL; Mielcarek N; Oliveira MLS
PLoS One; 2020; 15(1):e0228055. PubMed ID: 31945121
[TBL] [Abstract][Full Text] [Related]
2. Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.
Salcedo-Rivillas C; Debrie AS; Miyaji EN; Ferreira JM; Raw I; Locht C; Ho PL; Mielcarek N; Oliveira ML
Clin Vaccine Immunol; 2014 Jul; 21(7):972-81. PubMed ID: 24807055
[TBL] [Abstract][Full Text] [Related]
3. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.
Oliveira ML; Miyaji EN; Ferreira DM; Moreno AT; Ferreira PC; Lima FA; Santos FL; Sakauchi MA; Takata CS; Higashi HG; Raw I; Kubrusly FS; Ho PL
PLoS One; 2010 May; 5(5):e10863. PubMed ID: 20523738
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
Vadesilho CF; Ferreira DM; Moreno AT; Chavez-Olortegui C; Machado de Avila RA; Oliveira ML; Ho PL; Miyaji EN
Microb Pathog; 2012; 53(5-6):243-9. PubMed ID: 22981893
[TBL] [Abstract][Full Text] [Related]
5. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.
Tostes RO; Rodrigues TC; da Silva JB; Schanoski AS; Oliveira ML; Miyaji EN
PLoS One; 2017; 12(1):e0170157. PubMed ID: 28103277
[TBL] [Abstract][Full Text] [Related]
6. Immune responses and protection against Streptococcus pneumoniae elicited by recombinant Bordetella pertussis adenylate cyclase (CyaA) carrying fragments of pneumococcal surface protein A, PspA.
Carneiro GB; Castro JT; Davi M; Miyaji EN; Ladant D; Oliveira MLS
Vaccine; 2023 Jun; 41(28):4170-4182. PubMed ID: 37236818
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice.
Lima FA; Miyaji EN; Quintilio W; Raw I; Ho PL; Oliveira ML
Vaccine; 2013 May; 31(20):2465-70. PubMed ID: 23541622
[TBL] [Abstract][Full Text] [Related]
8. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
[TBL] [Abstract][Full Text] [Related]
9. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
[TBL] [Abstract][Full Text] [Related]
10. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
[TBL] [Abstract][Full Text] [Related]
11. Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection.
Rodrigues TC; Oliveira MLS; Soares-Schanoski A; Chavez-Rico SL; Figueiredo DB; Gonçalves VM; Ferreira DM; Kunda NK; Saleem IY; Miyaji EN
PLoS One; 2018; 13(1):e0191692. PubMed ID: 29360883
[TBL] [Abstract][Full Text] [Related]
12. Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections.
Zhang Y; Guo X; Guo M; Chen X; Li B; Yu J; Gu T; Kong W; Wu Y
Immunol Res; 2019 Oct; 67(4-5):398-407. PubMed ID: 31773490
[TBL] [Abstract][Full Text] [Related]
13. Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role.
Alonso S; Reveneau N; Pethe K; Locht C
Infect Immun; 2002 Aug; 70(8):4142-7. PubMed ID: 12117922
[TBL] [Abstract][Full Text] [Related]
14. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
15. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy.
Goulart C; Rodriguez D; Kanno AI; Lu YJ; Malley R; Leite LC
Vaccine; 2017 Mar; 35(13):1683-1691. PubMed ID: 28242071
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
17. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains.
Yu J; Chen X; Li B; Gu T; Meng X; Kong W; Wu Y
Immunol Res; 2018 Aug; 66(4):528-536. PubMed ID: 30128745
[TBL] [Abstract][Full Text] [Related]
18. Restricted antibody response to Bordetella pertussis filamentous hemagglutinin induced by whole-cell and acellular pertussis vaccines.
Asgarian-Omran H; Golara M; Abdolmaleki S; Navabi SS; Alipour H; Khoshnoodi J; Hemmati A; Zarei S; Jeddi-Tehrani M; Shokri F
Infect Dis (Lond); 2016 Feb; 48(2):127-32. PubMed ID: 26439274
[TBL] [Abstract][Full Text] [Related]
19. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
Miyaji EN; Dias WO; Tanizaki MM; Leite LC
FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model.
Watanabe M; Komatsu E; Abe K; Iyama S; Sato T; Nagai M
Vaccine; 2002 Jan; 20(9-10):1429-34. PubMed ID: 11818163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
